lc, my comment was based on the valuation a company with no profit yet trading at 1 times sales (based on current share price times 8 million shares). Only profitability and/or exponential sales growth will take this company above this sales multiple. What I wrote about Musclepharm was based on my perception of the company's financial condition, its future potential and limited information available. If you have time, look at their financial statement and go to the cash flow statement and try to find out whether the non-cash compensation to the two consultants were added to net income to arrive at operating cash flow. Operating cash flow before working capital items is the most important thing in the financials to determine whether a company needs more money in future. I don't know why the non-cash compensation was not added, and I am still trying to figure that out. I sure said they needed money and that's why they raised another $6 million. And yes, they need more money to execute their business plan, IMO. I could be wrong this time again, but there is no information asymmetry now. Investors now know enough about this company and market will not have crazy valuation for this company unless it is substantiated by some key numbers. We all go by our own judgement. That's why all trades have two parties - I am on the seller's side and I understand you are on the other side. That's why investing is so fascinating.
Market Data 
Markets 
AI
